Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect

Thanaporn Ratchataswan, Tina M. Banzon, Jacob P. Thyssen, Stephan Weidinger, Emma Guttman-Yassky, Wanda Phipatanakul

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a heterogeneous disease affecting both children and adults. The treatment of moderate-to-severe forms of AD is challenging, as topical corticosteroids are often insufficient to achieve disease control or inappropriate and off-label use of immunosuppressants may have significant undesirable side effects. The development of targeted biologic therapies specifically for AD is thus highly desirable. Dupilumab is the only biologic therapy that is Food and Drug Administration approved for the treatment of moderate-to-severe AD in patients 6 years and older, with consistent long-term efficacy and safety trial data. In this article, we review the mechanisms, safety, and efficacy of dupilumab from recent clinical trials, and we review the current data, mechanism of action, clinical efficacy, and limitations of new biologics currently in phase 2 and 3 clinical trials (lebrikizumab, tralokinumab, nemolizumab, tezepelumab, and ISB 830).

Original languageEnglish
Pages (from-to)1053-1065
Number of pages13
JournalJournal of Allergy and Clinical Immunology: In Practice
Issue number3
StatePublished - Mar 2021


  • Atopic dermatitis
  • Biologic therapy
  • Dupilumab
  • Eczema
  • GBR 830
  • ISB 830
  • Lebrikizumab
  • Nemolizumab
  • Tezepelumab
  • Tralokinumab


Dive into the research topics of 'Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect'. Together they form a unique fingerprint.

Cite this